Salivary antibodies induced by BA.4/BA.5-convalescence or bivalent booster Immunoglobulin vaccination protect against novel SARS-COV-2 variants of concern

Salivary antibodies induced by BA.4/BA.5-convalescence or bivalent booster Immunoglobulin vaccination protect against novel SARS-COV-2 variants of concern

ABSTRACT Currently, SARS-CoV-2 Omicron BA.5 subvariants BF.7 and BQ.1.1 are rapidly emerging worldwide. To evaluate the SARS-CoV-2-neutralizing capacity of sera and saliva from triple vaccinated individuals, either boosted with an adapted bivalent COVID-19 vaccine or recovered from BA.4/BA.5 infecti...

Full description

Bibliographic Details
Main Authors: Gabriel Diem, Stefanie Dichtl, Viktoria Zaderer, Cornelia Lass-Flörl, Markus Reindl, Gaia Lupoli, Christopher Dächert, Maximilian Muenchhoff, Alexander Graf, Helmut Blum, Oliver T. Keppler, Doris Wilflingseder, Wilfried Posch
Format: Article
Language:English
Published: American Society for Microbiology 2023-10-01
Series:Microbiology Spectrum
Subjects:
SARS-CoV-2
variants of concern
salivary antibodies
Omicron
vaccination
convalescence
Online Access:https://journals.asm.org/doi/10.1128/spectrum.01793-23

Internet

https://journals.asm.org/doi/10.1128/spectrum.01793-23

Similar Items